ODN 2006 VacciGrade™

Product Unit size Cat. code Docs. Qty. Price

ODN 2006 VacciGrade™

CpG ODN, Class B (human) - TLR9 agonist

Show product

1 mg


CpG ODN, type B (human) - TLR9-based vaccine adjuvant

TLR9 activation with ODN 2006
TLR9 activation with ODN 2006

ODN 2006 VacciGrade™ (ODN 7909) is a Class B CpG oligonucleotide (ODN) with a preference for the human Toll-like receptor 9 (TLR9). ODN 2006 is a short synthetic single-stranded DNA molecule containing unmethylated CpG dinucleotides (CpG motifs). These unmethylated CpG motifs mimic microbial DNA and act as immunostimulants via TLR9. 

More details More details


Class B (Type K) CpG ODNs, such as ODN 2006, contain a full phosphorothioate backbone with one or more CpG dinucleotides. They strongly activate B cells but weakly stimulate IFN-α secretion in plasmacytoid dendritic cells [1]. Moreover, they generate Th1-dominant immune responses and thus, are potential adjuvants for human vaccines to elicit protective Th1 immunity [2]. 

 ODN 2006 has been tested as an adjuvant in numerous animal models  [3-5]. Research has demonstrated that ODN 2006 is an effective adjuvant for stimulating antibody [8-9] and interferon-mediated cellular immune responses [5].

InvivoGen's ODN 2006 is a strong TLR9 agonist verified using our HEK-Blue™ reporter cell lines expressing human or mouse TLR9 (see figure)Moreover, ODN 2006 activates the hTLR9-dependent NF-κB and IRF pathways, as assessed using our THP1-Dual™ hTLR9 reporter cell line expressing two reporter genes, for the NF-κB-inducible SEAP and IRF-inducible Lucia luciferase, as well as hTLR9 (see figure). 


VacciGrade™ is a high-quality pre-clinical grade, suitable for in vivo use.
A standard grade ODN 2006 for in vitro assays is also available.

ODN 2006 VacciGrade™​ is for research use only, and not for human or veterinary use. It is not a pharmaceutical preparation fit for vaccine manufacturing.


Get more information about CpG ODNs Classes.

Read our review Read our review on TLR9 agonists: double-edged sword for immune therapies.




1. Krieg A.M. et al., 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374(6522):546-9.
2. Chu RS, et al., 1997. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med.;186(10):1623-31.
3. Hartmann G. et al., 2000. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164(3): 1617 - 1624.
4. Conforti VA. et al., 2007. The effectiveness of a CpG motif-based adjuvant (CpG ODN 2006) for LHRH immunization. Vaccine 25: 6537-43.
5. Zhang Y. et al., 2003. CpG ODN 2006 and IL-12 are comparable for priming Th1 lymphocyte and IgG responses in cattle immunized with a rickettsial outer membrane protein in alum. Vaccine 21:3307-18.


Species-driven TLR9 differential responses
Species-driven TLR9 differential responses

Species-driven TLR9 differential responses. HEK-Blue™ mTLR9 and HEK-Blue™ human (h)TLR9 cells were cultured in HEK-Blue™ Detection reagent and stimulated for 24 hours with 100 nM of the following TLR9 agonists: ODN 1826, ODN 2006, and ODN 2007. Human TNF-α (1 ng/ml) served as an NF-κ-positive control. After 24h incubation, the NF-κB-induced SEAP activity was assessed by measuring the SEAP level in the supernatant. Data are shown as optical density (OD) at 650 nm (mean ± SEM).

NF-κB response induced by ODN 2006
NF-κB response induced by ODN 2006

THP1-Dual™ hTLR9 cells were incubated with increasing concentrations of ODN 2006. After overnight incubation, the NF-κB response was assessed by measuring the SEAP activity using QUANTI-Blue™ Solution. Data are shown as a fold increase (mean ± SEM).

IRF response induced by ODN 2006
IRF response induced by ODN 2006

THP1-Dual™ hTLR9 cells were incubated with increasing concentrations of ODN 2006. After overnight incubation, the interferon regulatory receptor (IRF) activity was assessed by measuring the Lucia luciferase activity in the supernatant using QUANTI‑Luc™ 4 Lucia/Gaussia. Data are shown as a fold increase (mean ± SEM).

Back to the top


ODN 2006 sequence: 5’-tcgtcgttttgtcgttttgtcgtt-3’ (24 mer)

Description: TLR9 agonist VacciGrade™

Synonyms: ODN 7909, PF_3512676

Polarization of adaptive immune response: Th1 response

Solubility: 2 mg/ml in physiological water

Working concentration: 20 - 50 μg/mouse

Quality control:

Back to the top


  • 1 mg (129.8 nmol) of sterile lyophilized ODN 2006 VacciGrade™.
  • 10 ml sterile endotoxin-free physiological water (NaCl 0.9%).

ODN 2006 VacciGrade™ is shipped at room temperature.

ODN 2006 VacciGrade™ should be stored at -20°C for up to 1 year.
Upon resuspension, prepare aliquots of ODN 2006 VacciGrade™ and store at -20°C.

Product is stable 6 months at -20°C when properly stored.

Avoid repeated freeze-thaw cycles.

Back to the top


VacciGrade™ is a high-quality pre-clinical grade. VacciGrade™ products are filter-sterilized (0.2 µm) and filled under strict aseptic conditions in a clean room*. The absence of bacterial contamination is assessed by a sterility test using a pharmacopeia-derived assay. The level of bacterial contaminants (endotoxins and lipoproteins) in each lot is verified using a LAL assay and/or a TLR2 and TLR4 reporter assay.
*Except for LPS VacciGrade™, which is prepared in a laminar flow hood dedicated to LPS.

Back to the top



Synthetic oligodeoxynucleotides containing unmethylated CpG motifs (CpG ODNs), such as ODN 1018, have been extensively studied as adjuvants [1]. These CpG motifs are present at a 20-fold greater frequency in bacterial DNA compared to mammalian DNA [2]. CpG ODNs are recognized by the Toll-like receptor 9 (TLR9), which is expressed on human B cells and plasmacytoid dendritic cells (pDCs), thereby inducing Th1-dominated immune responses [3]. Pre-clinical studies, conducted in rodents and non-human primates, as well as human clinical trials, have demonstrated that CpG ODNs can significantly improve vaccine-specific antibody responses [1]. Three types of stimulatory CpG ODNs have been identified, types A, B, and C, which differ in their immune-stimulatory activities [4-5]. 


Toll-like receptor 9

The Toll-like Receptor 9 (TLR9) is an endosomal receptor that triggers NF-κB- and interferon regulatory factor (IRF)-mediated pro-inflammatory responses upon the recognition of unmethylated cytosine-phosphorothioate-guanosine (CpG) forms of DNA [6-8]. Unmethylated CpG dinucleotides are a hallmark of microbial (bacterial, viral, fungal, and parasite) DNA, as well as mitochondrial self-DNA [8,9]. These TLR9 agonists can be mimicked by synthetic oligonucleotides containing CpG motifs (CpG ODNs), which have been extensively studied to improve adaptive immune responses in the context of vaccination [6,8].

TLR9 is mainly expressed in subsets of Dendritic Cells and B cells of all mammals. In rodents, but not in humans, TLR9 is also expressed in monocytes and macrophages [8]. The structure of the receptor varies by 24% between human TLR9 (hTLR9) and mouse TLR9 (mTLR9) [8]. They recognize different CpG motifs, the optimal sequences being GTCGTT and GACGTT for hTLR9 and mTLR9, respectively [10].



1. Steinhagen F. et al., 2011. TLR-based immune adjuvants. Vaccine 29(17):3341-55.
2. Hemmi H. et al., 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740-5.
3. Coffman RL. et al., 2010. Vaccine adjuvants: Putting innate immunity to work. Immunity 33(4):492-503.
4. Krug A. et al., 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol, 31(7): 2154-63.
5. Marshall JD. et al., 2005. Superior activity of the type C class of ISS in vitro and in vivo across multiple species. DNA Cell Biol. 24(2):63-72.
6. Kumagai Y. et al., 2008. TLR9 as a key receptor of the recognition of DNA. Adv. Drug. Deliv. Rev. 60(7):795-804.
7. Heinz L.X. et al., 2021. TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9. Nature. 581(7808):316-322.
8. Kayraklioglu N. et al., 2021. CpG oligonucleotides as vaccine adjuvants. DNA Vaccines: Methods and Protocols. Methods in Molecular Biology. Vol. 2197. p51-77.
9. Kumar V., 2021. The trinity of cGAS, TLR9, and ALRs: guardians of the cellular galaxy against host-derived self-DNA. Front. Immunol. 11:624597.
10. Bauer S. et al., 2001. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA, 98(16):9237-42.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty